For patients with IgG kappa multiple myeloma receiving an IgG kappa mAb (i.e., daratumumab), how important is it clinically to use an interference assay if they're in a VGPR to see if their M-spike might actually be 0?
For example, would you use a tool like the Hydrashift assay? Would this change your management?
I'd like to second the concept, "why do it unless ...